ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 889

Podocytes Take Up Adsdna Autoantibody Complexes

Anja Hillmann1, Elisabeth Jung2, Annika Engbers1, Hedda Wardemann3, Annett M. Jacobi2 and Thomas Pap4, 1Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany, 2Rheumatology Internal Medicine D, University Hospital Münster, Münster, Germany, 3Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 4Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Kidney, Lupus and autoantibodies

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic lupus erythematosus (SLE) is an autoimmune disease, resulting in inflammation and tissue damage in several organs. This autoimmune reaction is caused by autoantibodies, e.g. against dsDNA (adsDNAabs). Most patients with SLE develop joint pain and about 70% develop renal symptoms, partly with lupus nephritis leading to proteinuria. It is still unclear why the kidney and especially the postmitotic podocytes are involved in such a dramatic manner during SLE.

Methods:

Antibodies were isolated from SLE-patients, cloned and produced recombinantly in HEK293 cells. Living podocytes were treated with equal amounts of adsDNAabs and control antibodies in time and concentration dependent experiments and examined by immunofluorescence and Western Blot. To investigate the uptake mechanism, antibodies were pretreated with DNaseI. To analyze the degradation mechanism, treated cells were incubated with e.g. Bafilomycin.

Results: adsDNAabs are taken up by cultivated podocytes selectively in a concentration and time dependent manner and turn up in cytosolic aggregates. After treatment of the antibodies with DNAseI, the uptake decreases significantly. In recovery experiments, we could show that these aggregates are eliminated over time in media without adsDNAabs. The aggregates co-localize with different autophagy related proteins. Western Blot analyzes show that autophagy is upregulated after treatment with adsDNAabs. The degradation of adsDNAabs is reduced in experiments under autophagy inhibiting conditions (treatment with Bafilomycin A) and number of aggregates after the inhibition of autophagy rises significantly up to twofold. The number of aggregates of podocytes treated with a control antibody or antibodies against other autoantigens (e.g. Ro) is almost zero.

Conclusion: Podocytes are postmitotic and highly complex cells. Loss of these cells leads to kidney injury and proteinuria. During lupus-nephritis, podocytes are destroyed. We could show that these cells take up adsDNAabs selectively in a complex with their target and are harmed by these antibody-aggregates. Our results indicate that the antibody-complexes in the cells are degraded via autophagy. This should be considered for future therapeutic approaches in lupus nephritis.


Disclosure:

A. Hillmann,
None;

E. Jung,
None;

A. Engbers,
None;

H. Wardemann,
None;

A. M. Jacobi,
None;

T. Pap,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/podocytes-take-up-adsdna-autoantibody-complexes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology